Pai V R, Mazumdar A T, Deshmukh C D, Bakshi A V, Parikh D M, Parikh P M, Mistry R C, Pathak K A
Department of Medical and Surgical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Med Oncol. 2003;20(1):1-5. doi: 10.1385/MO:20:1:1.
Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerated, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck.
晚期头颈癌在印度是一个重大的治疗难题。异环磷酰胺作为单一药物在头颈部鳞状细胞癌中已显示出显著活性。在本研究中，我们介绍了对总共519例患者在新辅助治疗中给予两个周期异环磷酰胺和顺铂的经验。完全缓解率为20%，总缓解率为80%。该治疗耐受性良好，无需降低剂量，也没有危及生命的副作用。我们认为，如此高的缓解率足以保证开展更多在新辅助治疗中使用基于异环磷酰胺的联合方案治疗头颈部鳞状细胞癌的研究。
